

31 March 2023

## **BEXIMCO PHARMACEUTICALS LIMITED**

### **Holdings in Company**

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, notes that two significant shareholders in Bangladesh have reported a trade between one another in the Company's Ordinary shares, which are only tradeable in Bangladesh, to the Dhaka Stock Exchange on 22 March 2023. This trade does not concern global depositary receipts admitted to trading on AIM in London.

IFIC Securities Limited sold 17m Ordinary shares at a price of TK. 135.00 per share to Absolute Construction and Engineering Limited who bought the 17m Ordinary shares at a price of TK. 135.00 per share between 14 and 20 March 2023.

As a result, IFIC Securities Limited now holds 4,780,000 Ordinary shares representing 1.07 per cent. of the total voting rights in the Company and Absolute Construction and Engineering Limited now holds 41,152,022 Ordinary shares representing 9.22 per cent. of the total voting rights in the Company.

**For further information, please visit [www.beximcopharma.com](http://www.beximcopharma.com) or enquire to:**

#### **Beximco Pharma**

Nazmul Hassan MP, Managing Director  
Tel: +880 2 58611001, Ext.20080

Mohammad Asad Ullah FCS  
Executive Director & Company Secretary  
Tel: 880 2 58611001, Ext. 10140

Mohammad Ali Nawaz, Chief Financial Officer  
Tel: +880 2 58611001, Ext.20030

#### **SPARK Advisory Partners Limited (Nominated Adviser)**

Mark Brady / Andrew Emmott  
Tel: +44 (0) 20 3368 3551 / 3555

#### **SP Angel Corporate Finance LLP (Broker)**

Vadim Alexandre / Abigail Wayne  
Tel: +44 (0) 20 3470 0470

#### **FTI Consulting**

Simon Conway / Victoria Foster Mitchell  
Tel: +44 (0) 20 3727 1000

#### **Notes to Editors**

#### **About Beximco Pharmaceuticals Limited**

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company

also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

HOLGZGFFGMMGFZM